MedTrace Logo

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

NCT07220954 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-05-18

No results posted yet for this study

Summary

This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234.

This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.

Conditions

  • Healthy Participants

Interventions

DRUG

AZD6234 Formulation 1

AZD6234 Formulation 1 will be administered as a single SC injection

DRUG

AZD6234 Formulation 2 (low concentration)

AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection

DRUG

AZD6234 Formulation 2 (high concentration)

AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection

DRUG

AZD6234 Formulation 3

AZD6234 Formulation 3 will be administered as a single SC injection

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-11
Primary Completion
2026-09-09
Completion
2027-04-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07220954 on ClinicalTrials.gov